Cyclacel pharmaceuticals announces $1 million private placement offering of convertible preferred stock

Kuala lumpur, malaysia, march 24, 2025 (globe newswire) -- cyclacel pharmaceuticals, inc. ("cyclacel") (nasdaq: cycc, nasdaq: cyccp), a biopharmaceutical company that develops innovative cancer medicine, today announced that it has entered into a securities purchase agreement for the sale of its convertible series e preferred stock (“preferred stock”) in a private placement to certain accredited investors yielding gross proceeds of $1.0 million before deducting offering expenses. the offering closed on march 21, 2025.
CYCC Ratings Summary
CYCC Quant Ranking